Cancer - August 2015 Archives

ROCHESTER, Minn. — About 20 percent of colorectal cancer patients have cancers that have spread (metastasized) beyond the colon at the time of their diagnosis. The liver is the most common site for these metastases. The approach to treating primary tumors within the colon and metastatic tumors in the liver continues to evolve; however, it typically involves chemotherapy plus surgical removal (resection) of both types of tumors. However, experts continue to debate whether surgical resection of primary tumors and metastatic tumors should be performed at the same time (synchronously) or in separate operations (sequentially). In the August issue of the Journal of Gastrointestinal Surgery, Mayo Clinic researchers provided a detailed comparison of patient outcomes associated with synchronous and sequential colorectal and liver resections in patients with stage IV colorectal cancer, identifying some benchmarks for surgical practice. MEDIA CONTACTS: Elizabeth Zimmermann Young, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

According to the American Cancer Society, about 21,000 women will be diagnosed with ovarian cancer this year ... and more than 14,000 will die from ...

ROCHESTER Minn. — A team of Mayo Clinic Cancer Center scientists has been awarded a Specialized Program of Research Excellence (SPORE) grant in multiple myeloma from the National Cancer Institute. The Mayo Clinic Cancer Center is one of only three cancer centers to receive a SPORE grant for multiple myeloma cancer research. “With project leaders from Mayo campuses in Arizona, Rochester and Florida, our SPORE team will study the genetic basis for myeloma, develop novel viral and immunologic therapies, and optimize the use of existing therapies with a goal of controlling and eventually curing this deadly disease,” says Leif Bergsagel, M.D., lead investigator. “Starting from the pioneering work of Robert Kyle, M.D., over the last half-century, the myeloma group at Mayo Clinic is one of the strongest in the world.” Journalists: Sound bites with Dr. Bergsagel are available in the downloads. MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu  https://www.youtube.com/watch?v=8XGjq_d96CI

A simple path to resilience From moving more and eating well to taking time to relax, discover simple things you can do to nurture ...

According to the American Cancer Society, about 21,000 women will be diagnosed with ovarian cancer this year ... and more than 14,000 will die from ...

https://www.youtube.com/watch?v=yGYTLOGZ40U   JACKSONVILLE, Fla. — Cancer researchers dream of the day they can force tumor cells to morph back to the normal cells they once were. Now, researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy. The finding, published in Nature Cell Biology, represents “an unexpected new biology that provides the code, the software for turning off cancer,” says the study’s senior investigator, Panos Anastasiadis, Ph.D., chair of the Department of Cancer Biology on Mayo Clinic’s Florida campus. Journalists: Sound bites with Dr. Anastasiadis are available in the downloads. MEDIA CONTACT: Kevin Punsky, Mayo Clinic Public Affairs, 904-953-0746, punsky.kevin@mayo.edu

According to the American Cancer Society, about 21,000 women will be diagnosed with ovarian cancer this year ... and more than 14,000 will die from ...

Preventing infections during chemotherapy Chemotherapy drugs can keep your body from fully protecting itself against infections. To stay safe, try these food, personal care and ...

https://www.youtube.com/watch?v=_Z1keOchjn8   The Trans Am Muscle Car Challenge promises to be a high-octane event Friday in Lexington, Ohio. But, one of the drivers is already ...

The high cost of cancer drugs Even with health insurance, out-of-pocket expenses for cancer drugs can be in the thousands, causing added stress. Some ...

  PHOENIX -- A multicenter study involving Mayo Clinic researchers has found that the National Cancer Institute's Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), was accurate, reliable and responsive, compared to other, established patient-reported and clinical measures. The study is published today in the journal JAMA Oncology. “In most cancer clinical trials, information on side effects is collected by providers who have limited time with their patients and current patient questionnaires are limited in scope and depth," says the study's lead author Amylou Dueck, Ph.D., a biostatistician on Mayo Clinic’s Arizona campus. "PRO-CTCAE is a library of items for patients to directly report on the level of each of their symptoms, to enhance the reporting of side effects in cancer clinical trials which is normally based on information from providers. The study itself is unprecedented as more than 100 distinct questions about symptomatic adverse events were validated simultaneously." Researchers recruited more than 1,000 patients from nine clinical practices across the U.S., including seven cancer centers. These patients reflected the geographic, ethnic, racial and economic diversity in cancer clinical trials. Patients in the study also had a wide range of cancer types. MEDIA CONTACT: Jim McVeigh, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

Gardening restores the body and soul Gardening helps you get some exercise, stay healthy and nourish your spirit. Your plants give back, too, with beauty ...